 ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the publication of the exebacase Phase 2 study results in the July 1, 2020 issue of the Journal of Clinical Investigation. The study results established clinical proof-of-concept for exebacase and informed the design of the ongoing Phase 3 DISRUPT Direct Lysis of Staph aureus Resistant Pathogen Trial study of exebacase for the treatment of patients with life-threatening Staph aureus bloodstream infections BSIs, including right-sided endocarditis. 